76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials
Journal of the American Academy of Dermatology · 2026-07 · 95 (1) · AB192
DOI: 10.1016/j.jaad.2026.04.783 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Academy of Dermatology, 2026-07. Verfasst von Srinivas Sidgiddi und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Sidgiddi, S., Gold, L. S., Gallo, R., Dhawan, S., Bayar, S., & Sidgiddi, S. (2026). 76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials. Journal of the American Academy of Dermatology, 95(1), AB192. https://doi.org/10.1016/j.jaad.2026.04.783
Vancouver
Sidgiddi S, Gold LS, Gallo R, Dhawan S, Bayar S, Sidgiddi S. 76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials. Journal of the American Academy of Dermatology. 2026;95(1):AB192. doi:10.1016/j.jaad.2026.04.783
BibTeX
@article{Sidgiddi2026,
author = {Sidgiddi, Srinivas and Gold, Linda Stein and Gallo, Richard and Dhawan, Sunil and Bayar, Shraddha and Sidgiddi, Srinivas},
title = {76863 Efficacy of Oral DFD-29, a Low-Dose Minocycline Formulation, by Baseline Rosacea Severity in Two Phase 3 Trials},
journal = {Journal of the American Academy of Dermatology},
year = {2026},
volume = {95},
number = {1},
pages = {AB192},
doi = {10.1016/j.jaad.2026.04.783}
}
EUVIMED